A good strategy as those companies have sunk money, are more knowledgeable and have probably lauded their expertise to stockholders. Also good strategy to wait until trial is unblinded to ‘aggressively’ pursue partnerships with big pharma. I have no problem with pursuing partnerships for a particular Leronlimab indication. We have a top flight law firm who will be watching our back to ensure that whomever is our partner, the agreement ensures the development of the drug to our benefit!